Literature DB >> 17851557

Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring.

V H J van der Velden, J M Wijkhuijs, J J M van Dongen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17851557     DOI： 10.1038/sj.leu.2404925

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

Review 1.  Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.

Authors:  Jacques J M van Dongen; Vincent H J van der Velden; Monika Brüggemann; Alberto Orfao
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

2.  Minimal residual disease assessment by next-generation sequencing. Better tools to gaze into the crystal ball?

Authors:  A Balduzzi
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

3.  Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL.

Authors:  M Kotrova; V H J van der Velden; J J M van Dongen; R Formankova; P Sedlacek; M Brüggemann; J Zuna; J Stary; J Trka; E Fronkova
Journal:  Bone Marrow Transplant       Date:  2017-02-27       Impact factor: 5.483

4.  Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.

Authors:  Prisca Theunissen; Ester Mejstrikova; Lukasz Sedek; Alita J van der Sluijs-Gelling; Giuseppe Gaipa; Marius Bartels; Elaine Sobral da Costa; Michaela Kotrová; Michaela Novakova; Edwin Sonneveld; Chiara Buracchi; Paola Bonaccorso; Elen Oliveira; Jeroen G Te Marvelde; Tomasz Szczepanski; Ludovic Lhermitte; Ondrej Hrusak; Quentin Lecrevisse; Georgiana Emilia Grigore; Eva Froňková; Jan Trka; Monika Brüggemann; Alberto Orfao; Jacques J M van Dongen; Vincent H J van der Velden
Journal:  Blood       Date:  2016-11-30       Impact factor: 22.113

Review 5.  Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?

Authors:  Michaela Kotrova; Jan Trka; Michael Kneba; Monika Brüggemann
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

Review 6.  Quality Control for IG /TR Marker Identification and MRD Analysis.

Authors:  Eva Fronkova; Michael Svaton; Jan Trka
Journal:  Methods Mol Biol       Date:  2022

7.  Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemia.

Authors:  Alexander A Morley; Sue Latham; Michael J Brisco; Pamela J Sykes; Rosemary Sutton; Elizabeth Hughes; Vicki Wilczek; Bradley Budgen; Katrina van Zanten; Bryone J Kuss; Nicola C Venn; Murray D Norris; Catherine Crock; Colin Storey; Tamas Revesz; Keith Waters
Journal:  J Mol Diagn       Date:  2009-03-26       Impact factor: 5.568

Review 8.  How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.

Authors:  Marie C Béné; Jaspal S Kaeda
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

Review 9.  Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches.

Authors:  Fatemeh Salari; Mohammad Shahjahani; Saeid Shahrabi; Najmaldin Saki
Journal:  Med Oncol       Date:  2014-10-07       Impact factor: 3.064

10.  Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.

Authors:  David Wu; Ryan O Emerson; Anna Sherwood; Mignon L Loh; Anne Angiolillo; Bryan Howie; Jennifer Vogt; Mark Rieder; Ilan Kirsch; Christopher Carlson; David Williamson; Brent L Wood; Harlan Robins
Journal:  Clin Cancer Res       Date:  2014-06-26       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.